Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research report released on Monday. The firm issued a hold rating on the biotechnology company’s stock.

Nabriva Therapeutics Price Performance

The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $8.45. The stock has a market cap of $45.46 million, a PE ratio of -0.07 and a beta of 1.53.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.